Back to Search
Start Over
China NMPA accepts VISEN Pharma's BLA for lonapegsomatropin to treat paediatric growth hormone deficiency
- Source :
- PharmaBiz. March 11, 2024
- Publication Year :
- 2024
-
Abstract
- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, announced that the Biologics License Application (BLA) for lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.786038904